New stable antibodies created
(Medical Xpress) -- Australian scientists have overcome one of the most pressing problems facing the pharmaceutical industry how to create antibodies that are stable enough to meet stringent requirements necessary for production in large quantities, injection into patients and long-term storage.
Members of the Antibody Engineering Laboratory at Sydneys Garvan Institute of Medical Research Dr Daniel Christ and PhD students Kip Dudgeon and Romain Rouet have developed specific mutations that universally increase the stability of antibody molecules. The breakthrough finding is published today in the early online edition of the Proceedings of the Academy of Science (PNAS), the journal of the United States National Academy of Sciences.
When we talk to collaborators in industry, we find that 30-50% of the antibody-based drugs they develop have to be put on hold because they dont meet quality tests that the companies or regulatory agencies such as the US Food and Drug Administration, require before marketing or approving these molecules, said Dr Christ.
Until now, the issue of antibody instability has been tackled on a case-by-case basis, which is only tinkering with the problem. When youre dealing with such a diverse population of molecules, you have to make sure that the method you develop is generally applicable and thats what weve done.
Produced by the immune system in response to infection there can be as many as 100 million different kinds of antibodies in the circulation of a single human being.
Antibodies have constant regions and variable regions, the latter determining the binding specificity of the molecule. The shape of the variable region will exactly match the antigen, or invader, in the same way as a lock matches a key.
With infinite variability of antibody structure comes varying levels of stability. It is fairly common, therefore, to have an antibody that is very good at binding to a specific antigen, but which is also very unstable. The mutations created by the Garvan team fix the stability problem without compromising the antigen binding properties of an antibody. Antibodies consist of two chains a heavy and a light chain and Dr Christ emphasises that mutations have to work with each chain individually and both chains in combination.
Typically youd have both chains present in a therapeutic molecule, as well as additional biological activity, such as the ability to bind to a cancer target, he said.
Our challenge was to maintain biological activity under very unnatural conditions, for which antibodies were not optimised by evolution. It is really when you take these molecules out of their natural environment, purify and concentrate them, that stresses become apparent. When used as a drug, antibodies are formulated at very high concentrations, for instance for delivery in a small syringe. You end up with an almost honey-like, highly viscous preparation. Under these conditions, antibodies can stick to surfaces like tubing and become entangled with one another. Our mutations make them much less sticky, much less entangled. They also make the antibodies more robust against common storage methods such as freeze drying.
The next step for the Garvan team will be to work with colleagues in the pharmaceutical industry to improve the stability of antibody therapeutics for the treatment of cancer and inflammatory conditions.
Journal reference: Proceedings of the National Academy of Sciences
Provided by Garvan Institute
- Recognizing blood poisoning quickly Dec 02, 2011 | not rated yet | 0
- 'Word of mouth' jobs elude ethnic migrants: study Jun 04, 2012 | not rated yet | 0
- Brain oscillations reveal that our senses do not experience the world continuously May 14, 2012 | not rated yet | 0
- The presence of water changes the structure of an antibiotic Apr 20, 2012 | not rated yet | 0
- First payload ready for next batch of Galileo satellites Apr 20, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...
Medications 4 hours ago | 5 / 5 (1) | 0
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications May 17, 2013 | not rated yet | 0
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications May 17, 2013 | 5 / 5 (1) | 0
(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...
Medications May 16, 2013 | 3.5 / 5 (2) | 0 |
(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...
Medications May 15, 2013 | not rated yet | 0
In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.
1 minute ago | not rated yet | 0 |
The number of young people diagnosed with type 2 diabetes has seen the sharpest rise over the last twenty years compared to a background of a general increase across the board, new University research has ...
1 hour ago | not rated yet | 0
Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...
2 minutes ago | not rated yet | 0
In ICU patients who have septic shock, the anatomic source of infection has a strong effect on the chances of survival, according to a new study from researchers in Canada.
18 seconds ago | not rated yet | 0
(Medical Xpress)—Scientists at King's College London have discovered that Vitamin D has the potential to significantly reduce the symptoms of asthma. The study, led by Professor Catherine Hawrylowicz from ...
1 hour ago | not rated yet | 0 |
(Medical Xpress)—Flinders University researchers are breaking new ground in a decade-long journey to pinpoint the function of two closely related proteins.
1 hour ago | not rated yet | 0 |